Background
M. pneumoniae is an important and common pathogen in respiratory infections in children [
1,
2].
M. pneumoniae pneumonia (MPP) accounted for 34.75% of community-acquired pneumonia (CAP) in hospitalized children from the Children’s Hospital of Soochow University from January 2011 to December 2015, with children over 5 years of age being more commonly affected than younger children [
3‐
6]. The acute phase of MPP can present with varying degrees of damage to the airway mucosa, which in severe cases can lead to mucosal embolization of the orifice and inflammatory stenosis or even occlusion. In addition, more than 30% of refractory MPP have been found to form bronchial mucus plugs (BMPs) [
7].
BMPs are endogenous bronchial foreign bodies that are caused by inflammation, bleeding, necrosis, abnormal secretion of bronchial mucus in the bronchus, mucus elimination obstacles, and then mucus accumulation and agglomeration in the bronchus, forming bronchial mucus plugging [
8,
9]. If not cleared in time, they can lead to bronchodilatation, pulmonary arrhythmia, occlusive bronchitis, and even acute respiratory failure and the blockage can be seriously life-threatening.
A study by Xu Q et al. showed that in patients aged 5 years and older, higher IL-10 levels and higher IFN-γ levels had an important predictive value for mucus plug formation [
10]. In the predicted nomogram, atelectasis and pleural effusion had the highest score and the highest weight, which is a powerful indicator for bronchoscopy intervention [
11]. The aim of this study was to analyze the risk factors for the formation of BMP in children with MPP. This evaluation of risk factors can assist clinicians to judge whether there is a possibility of BMP formation and ascertain the opportunity for reasonable treatment. Thus, it has important significance for reducing the occurrence of irreversible damage.
Materials and methods
Patients and data collection
This retrospective study was conducted in the Children’s Hospital of Soochow University. A total of 255 children who met the diagnosis of MPP were selected and treated with bronchoscopy during hospitalization from February 2015 to December 2019. The age range of the selected 255 children with MPP ranged from 2 months to 16 years. They all met the diagnostic criteria of the MPP diagnosis and treatment expert consensus (2015 version) for children. The clinical manifestations were fever, cough, and dyspnea, and with or without other systemic manifestations, such as dry lungs and wet rales, with signs of pulmonary consolidation and changes in lung imaging. In addition, the conditions that needed to be met were a serum MP-IgM > 1.1 or nasopharyngeal aspirates (NPA) MP-DNA > 1.0 × 105 copies/L. The exclusion criteria included those patients with chronic lung disease, recurrent respiratory tract infections, recurrent wheezing or a medical history of asthma, bronchopulmonary dysplasia, immunosuppression or defective disease, severe heart, liver, kidney disease, malignant tumors, and incomplete case information.
Laboratory tests were completed within 24 h after the children were admitted to the hospital, including neutrophil, CRP, LDH, DD, MP-IgM, PA levels, and NPAs. Demographic and clinical data of 255 children with MPP, including epidemiological, clinical, laboratory, and radiological characteristics, and bronchoscopy results, as well as treatments and outcomes, were collected and recorded.
Fiberoptic bronchoscopy
The children were fasted for 4–6 h prior to surgery. Atropine (0.01–0.02 mg/kg) and midazolam (0.1–0.3 mg/kg, the maximum amount was 4 mg/time) were injected intramuscularly 30 min prior to surgery. A solution of 2% lidocaine was swallowed nasally and orally three to four times, and 1% rosemary nasal drops were administered to the right nose. The choice of bronchoscopy model depended on patient age. The bronchoscope reached the openings of the trachea and the left and right bronchi through the nose and epiglottis. The front end of the bronchoscope reached the lesion and was then embedded in the lumen. Bronchial alveolar lavage was performed using 0.9% saline at 37 °C. For local lavage, where it was difficult to remove the mucus tie, it was removed with a brush or biopsy forceps and slowly pulled out of the fiberoptic bronchoscope.
Definitions
According to the performance of bronchoscopy, patients were divided into a mucous plug group and a control group. In the mucus group, the sputum plugs could be seen in the bronchial cavity of the lungs that blocked the lumen, and some plastic sputum plugs had formed. These are not easily removed and require the use of a brush. Some even require the use of foreign body pliers. In the control group, there were no mucus plugs in the lumen of the bronchus under the bronchoscope, but a few flocculent or thin secretions in the lumen could be seen.
Statistical analysis
SPSS25.0 statistical software was used for the data analysis. Measurement data conforming to a normal distribution are expressed as means ± standard deviations (x ± s). The comparison between the two groups used an independent sample t test. Non-normal distribution data is expressed as the median, and the comparison between the two groups used the Wilcoxon rank sum test. A P < 0.05 was considered statistically significant. The count data is expressed as a percentage (%), and a comparison between the groups was performed using a χ2 test. A logistic regression analysis of the risk factors related to intratracheal mucus plug formation in children with MPP was also performed (variable selection criteria were P < 0.05 and elimination criteria were P > 0.1; test level was bilateral α = 0.05). The receiver operating characteristic (ROC) curve was drawn, and the area under curve (AUC) was used to evaluate the predictive value of each independent risk factor in the formation of mucus plugs. A P < 0.05 was considered statistically significant.
Discussion
In recent years, with the increase in the incidence of MPP and the resistance to macrolide antibiotics, the incidence of refractory and severe MPP has increased. Studies have shown that BMP may become an important factor in the difficulty of MPP treatment [
12]. The results of this study suggest that clinical variables, including a lower PA level (≤144.5 mg/L), later corticosteroid therapy (≥4.5 d), a higher CRP level (≥12.27 mg/L), and a higher LDH level (≥462.65 U/L) were significantly associated with presence of BMP in children with MPP.
Xu Q et al. found that CRP, LDH, age, and fever duration were associated with the formation of BMPs in children with refractory
Mycoplasma pneumoniae pneumonia (RMPP) [
10]. Xu X et al. did not find a significant difference in serum LDH and CRP levels between the children with and without BMPs [
13]. It was found in this study that a CRP ≥12.27 mg/L and an LDH ≥462.65 were associated with BMP formation in children with MPP. This is related to the body’s excessive immune inflammatory response that leads to a numerous inflammatory factors. These inflammation factors further lead to serious airway mucosal damage, ciliary clearance dysfunction, and epithelial cell shedding, eventually forming a mucus plug to block the airway.
In contrast to previous studies, this study showed that the PA level had a higher predictive value. A PA ≤144.5 mg/L was associated with BMP formation in children with MPP. PA is a negative acute phase protein synthesized by the liver and is a non-specific host defense substance. Therefore, in an acute infection, the PA serum level can be rapidly reduced. Previous studies have found that PA is associated with the severity and prognosis of many diseases [
13]. Shen et al. conducted a retrospective analysis of 174 children with community-acquired pneumonia (CAP) and found that the sensitivity of PA to diagnose CAP was higher than that of other inflammation indicators, which is an independent protective factor for children with CAP. Combined with CRP, PA can effectively improve the diagnostic efficiency of children’s CAP and assess the severity of pneumonia [
14]. Research by Wang et al. showed that the PA level can reflect the severity of severe MPP, suggesting that the PA level may become an objective indicator for predicting the progress of severe MPP [
15].
In addition, it was found that earlier use of corticosteroid (CS) therapy can reduce the formation of BMP in children with MPP. The optimal threshold was less than 4.5 days. CS therapy has a direct inhibitory effect on many inflammatory cells, which can inhibit neutrophil apoptosis, promote eosinophil apoptosis, and reduce the number of mast cells in the airway [
16‐
18]. CS therapy can also inhibit inflammatory factors, improve clinical symptoms, reduce airway microvascular leakage, and reduce BMP production [
19,
20].
In this study, the predictive values of the various risk factors for mucus plug formation were different, and they were assigned a predictive value according to their OR value. Among them, a PA ≤144.5 mg/L was three points; a CRP ≥12.27 mg/L and an LDH ≥462.65 U/L was two points each; and a time of CS therapy application of ≥4.5 d was one point. Therefore, children who met the above indicators obtained the highest score of 8 points. According to the scores, MPP patients with 7–8 points belonged to the high-risk group for BMP formation. For example, an MPP child with a PA level of ≤144.5 mg/L, CS therapy after 4.5 d, a CRP level of ≥12.27 mg/L, and an LDH level of ≥462.65 U/L strongly indicated the presence of a BMP.
This study had some limitations. First, laboratory samples were not collected for the same period as the presence of disease, which produced a bias. Second, a prospective study is required to further confirm the reliability for this retrospective study. Third, with the limited number of cases, it was difficult to make the number of cases in the two groups similar.
Conclusions
PA level, timing of CS therapy use (use in the first few days), CRP level, and LDH level were independent risk factors for MPP mucus plug formation. According to the scoring system used in this study, the higher the score of children with MPP, the higher the risk of forming BMP. The scoring system does have the potential to be used for the identification of BMP in children with MPP, thereby contributing to a rational therapeutic choice.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.